1. Home
  2. SPOK vs LRMR Comparison

SPOK vs LRMR Comparison

Compare SPOK & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spok Holdings Inc.

SPOK

Spok Holdings Inc.

HOLD

Current Price

$13.09

Market Cap

267.8M

ML Signal

HOLD

Logo Larimar Therapeutics Inc.

LRMR

Larimar Therapeutics Inc.

HOLD

Current Price

$3.11

Market Cap

276.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPOK
LRMR
Founded
2004
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
267.8M
276.7M
IPO Year
1992
N/A

Fundamental Metrics

Financial Performance
Metric
SPOK
LRMR
Price
$13.09
$3.11
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$16.71
AVG Volume (30 Days)
164.4K
1.2M
Earning Date
02-25-2026
11-05-2025
Dividend Yield
9.45%
N/A
EPS Growth
12.68
N/A
EPS
0.80
N/A
Revenue
$139,739,000.00
N/A
Revenue This Year
$4.11
N/A
Revenue Next Year
$2.63
N/A
P/E Ratio
$16.53
N/A
Revenue Growth
1.47
N/A
52 Week Low
$12.26
$1.61
52 Week High
$19.31
$5.37

Technical Indicators

Market Signals
Indicator
SPOK
LRMR
Relative Strength Index (RSI) 48.07 35.77
Support Level $12.86 $3.12
Resistance Level $13.35 $3.62
Average True Range (ATR) 0.25 0.21
MACD 0.04 -0.04
Stochastic Oscillator 55.55 1.10

Price Performance

Historical Comparison
SPOK
LRMR

About SPOK Spok Holdings Inc.

Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Share on Social Networks: